Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Minimal Residual Disease (MRD) detection has emerged as an independent factor in
clinical and pathological cancer assessment offering a highly effective method for predicting …

Abstract Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy
selection and monitor treatment response in patients with metastatic cancer. However …

PURPOSE Identification of predictors for overall survival (OS) allows timely detection of
clinical efficacy signals and therefore facilitates treatment decisions. We assessed the …

Colon cancer is a major cause of cancer-related death. Despite recent improvements in the
treatment of colon cancer, new strategies to improve the overall survival of patients are …

Simple Summary Circulating tumor DNA, or ctDNA, are fragments of tumor DNA that can be
detected in the blood of patients with colorectal cancer. Measuring ctDNA levels in the blood …

We investigated whether early circulating tumor DNA (ctDNA) changes, measured using
digital PCR (dPCR), can predict later chemotherapy responses in esophageal squamous …

Molecular genetic analysis is an integral part of colorectal cancer (CRC) management. The
choice of systemic therapy for CRC is largely based on the results of tumor molecular …

Emerging new mutations after treatment can provide clues to acquired resistant
mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive …

Background Liquid biopsy is a novel tool in oncology. It provides minimally invasive
detection of tumor specific DNA. This review summarizes data on presence of circulating …